What does EZI Biolab do?

EZI Biolab is a wholesaler in Oupeye. Private Limited, started on 2 November 2012, 1 establishment.

What is the address of EZI Biolab?

The registered office of EZI Biolab is located at Rue du Broux 37, 4680 Oupeye.

Is EZI Biolab still active?

Yes. According to the CBE (30 October 2026) EZI Biolab is active, legal situation “Normale toestand”, started on 2 November 2012.

Is EZI Biolab registered on Peppol?

Yes, EZI Biolab is registered on the Peppol network with ID 0208:0500516337.

What is the enterprise number of EZI Biolab?

The enterprise number of EZI Biolab is BE0500516337.

When was EZI Biolab founded?

EZI Biolab was founded on 2 November 2012.

Who are the directors of EZI Biolab?

According to the 2025 annual accounts, the directors of EZI Biolab are: Isabelle MOURAD, Etienne CAVALIER.

Is EZI Biolab a reliable company?

Databakkes does not pass judgement; this is what the sources say: Active according to the CBE since 2 November 2012; 5 annual accounts filed, latest fiscal year 2025; 2 directors known from the annual account.

How much profit did EZI Biolab make in 2025?

EZI Biolab recorded a loss after taxes of € 20,694 in financial year 2025.

What is the revenue of EZI Biolab?

As a small company, EZI Biolab is not required to publish revenue in its annual accounts. In financial year 2025, its added value was € 79,847.

EZI Biolab (Private Limited) - Oupeye - BE0500516337

Dossier EZI Biolab, printed on 30 October 2026 from databakkes.be/en/0500516337/ezi-biolab. Sources: CBE, National Bank of Belgium, Belgian Official Gazette.

Warning lights

Signals from the annual accounts, the CBE and the Official Gazette, each with its threshold and source. No score, no verdict.

Two loss years in a row NBB

Negative result in 2024 and 2025.
Tight liquidity NBB

Cash and receivables cover 52 % of short-term debt in 2025; threshold 65 %.

Financials

Financial year 2025

EZI Biolab from Oupeye, company number BE0500516337, closed financial year 2025 with a result of € -20,694 after tax. For that financial year EZI Biolab recorded a gross margin of € 79,847 and equity of € 152,455. Compared with financial year 2024, the result moved from € -5,617 to € -20,694. The company made a loss. The company holds a healthy buffer. Debts are under control. The most recent annual accounts were filed with the National Bank of Belgium on June 4, 2026.

What it is worth Healthy

€ 152,455

▼ 12% vs 2024

Assets minus debts, by the books. What is left if everything were sold and paid today.

Loss Caution

€ -20,694

▼ 268 % more loss than in 2024

Profit after tax over the fiscal year.

Cash in the bank

€ 51,906

▼ 9% vs 2024

Cash and bank balances on the last day of the fiscal year.

Where the profit goes Caution

Loss, nothing to pay out

Reserves fell to € 127,455.

People and assets in 2025

Wage cost

€ 48,673

▲ 4% vs 2024

Payroll staff only. What the director pays themselves is already netted into the gross margin and is not shown separately in the accounts.

Vehicles and equipment

€ 42,847

▼ 25% vs 2024

Book value of vehicles, furniture and equipment.

Debts at end 2025

Bank debt ≈ 10 years to go The accounts give the long-term loan and the part due within the year. The remainder divided by that part is the number of years at an equal pace; a new loan or early repayment changes it.

€ 337,852

▼ 8% vs 2024

€ 33,869 is repaid this year. At this pace the long-term loan is gone in ≈ 10 years.

Owed to suppliers

€ 11,360

▲ 16% vs 2024

Supplier invoices still open on the last day of the fiscal year.

Taxes and wages

€ 29,085

▼ 1% vs 2024

Taxes, VAT and social contributions still to pay.

Key figures per fiscal year Download key figures (CSV)
	2022	2023	2024	2025	Change 2024 → 2025
Gross margin	€ -9,432 Gross margin 2022: € -9,432 First fiscal year in the series	€ 60,649 Gross margin 2023: € 60,649 ▲ € 70,080 vs 2022 (€ -9,432) Favourable step	€ 97,922 Gross margin 2024: € 97,922 ▲ 61% vs 2023 (€ 60,649) Favourable step	€ 79,847 Gross margin 2025: € 79,847 ▼ 18% vs 2024 (€ 97,922) Unfavourable step	▼ 18%
Profit after taxes	€ -35,256 Profit after taxes 2022: € -35,256 First fiscal year in the series	€ 13,621 Profit after taxes 2023: € 13,621 ▲ € 48,877 vs 2022 (€ -35,256) Favourable step	€ -5,617 Profit after taxes 2024: € -5,617 ▼ € 19,238 vs 2023 (€ 13,621) Unfavourable step	€ -20,694 Profit after taxes 2025: € -20,694 ▼ € 15,077 vs 2024 (€ -5,617) Unfavourable step	▼ € 15,077
Equity	€ 165,145 Equity 2022: € 165,145 First fiscal year in the series	€ 178,766 Equity 2023: € 178,766 ▲ 8% vs 2022 (€ 165,145) Favourable step	€ 173,149 Equity 2024: € 173,149 ▼ 3% vs 2023 (€ 178,766) Unfavourable step	€ 152,455 Equity 2025: € 152,455 ▼ 12% vs 2024 (€ 173,149) Unfavourable step	▼ 12%
Total debts	€ 420,616 Total debts 2022: € 420,616 First fiscal year in the series	€ 398,272 Total debts 2023: € 398,272 ▼ 5% vs 2022 (€ 420,616) Favourable step	€ 475,321 Total debts 2024: € 475,321 ▲ 19% vs 2023 (€ 398,272) Unfavourable step	€ 447,287 Total debts 2025: € 447,287 ▼ 6% vs 2024 (€ 475,321) Favourable step	▼ 6%
Cash	€ 134,590 Cash 2022: € 134,590 First fiscal year in the series	€ 95,907 Cash 2023: € 95,907 ▼ 29% vs 2022 (€ 134,590) Unfavourable step	€ 57,002 Cash 2024: € 57,002 ▼ 41% vs 2023 (€ 95,907) Unfavourable step	€ 51,906 Cash 2025: € 51,906 ▼ 9% vs 2024 (€ 57,002) Unfavourable step	▼ 9%
Land & buildings	€ 369,073 Land & buildings 2022: € 369,073 First fiscal year in the series	€ 413,544 Land & buildings 2023: € 413,544 ▲ 12% vs 2022 (€ 369,073) Unchanged	€ 417,589 Land & buildings 2024: € 417,589 ▲ 1% vs 2023 (€ 413,544) Unchanged	€ 400,359 Land & buildings 2025: € 400,359 ▼ 4% vs 2024 (€ 417,589) Unchanged	▼ 4%
Retained profit	€ 140,145 Retained profit 2022: € 140,145 First fiscal year in the series	€ 153,766 Retained profit 2023: € 153,766 ▲ 10% vs 2022 (€ 140,145) Favourable step	€ 148,149 Retained profit 2024: € 148,149 ▼ 4% vs 2023 (€ 153,766) Unfavourable step	€ 127,455 Retained profit 2025: € 127,455 ▼ 14% vs 2024 (€ 148,149) Unfavourable step	▼ 14%
Bank debt	€ 345,032 Bank debt 2022: € 345,032 First fiscal year in the series	€ 324,750 Bank debt 2023: € 324,750 ▼ 6% vs 2022 (€ 345,032) Favourable step	€ 367,541 Bank debt 2024: € 367,541 ▲ 13% vs 2023 (€ 324,750) Unfavourable step	€ 337,852 Bank debt 2025: € 337,852 ▼ 8% vs 2024 (€ 367,541) Favourable step	▼ 8%
Balance sheet total	€ 585,761 Balance sheet total 2022: € 585,761 First fiscal year in the series	€ 577,038 Balance sheet total 2023: € 577,038 ▼ 1% vs 2022 (€ 585,761) Unchanged	€ 648,470 Balance sheet total 2024: € 648,470 ▲ 12% vs 2023 (€ 577,038) Unchanged	€ 599,741 Balance sheet total 2025: € 599,741 ▼ 8% vs 2024 (€ 648,470) Unchanged	▼ 8%

Key figures of EZI Biolab, fiscal years 2022 to 2025, from the annual accounts filed with the National Bank of Belgium.Next annual account (fiscal year 2026) expected before 31 July 2027.

What happened to EZI Biolab?

What happened at EZI Biolab in recent years, according to the Belgian Official Gazette, the CBE and the National Bank:

Jun 4, 2026 New annual accounts for financial year 2025: loss of € 20,694. Source: NBB ↗
2021 Isabelle MOURAD became a director. NBB
2021 Etienne CAVALIER became a director. NBB
Nov 2, 2012 Start of the company according to the CBE. KBO
Oct 22, 2012 New establishment in Ans. KBO

In short

From € 35,256 loss in 2022 to € 20,694 loss in 2025.

Paid € 2,318 in corporate taxes since 2022.

Best year ever: 2023, with € 13,621 profit.

Original PDFs at the National Bank ↗

Management

Isabelle MOURAD Etienne CAVALIER

EZI Biolab

European Society for Clinical and Economic Aspects of Osteoporosis, Osteoarthritis and Musculoskeletal Diseases

Behind EZI Biolab are Isabelle MOURAD and Etienne CAVALIER. Etienne CAVALIER is also behind European Society for Clinical and Economic Aspects of Osteoporosis, Osteoarthritis and Musculoskeletal Diseases.

Directors

According to the 2025 annual accounts

Isabelle MOURAD

Director

since 2021

Etienne CAVALIER

Director

Also active at: European Society for Clinical and Economic Aspects of Osteoporosis, Osteoarthritis and Musculoskeletal Diseases

since 2021

Establishments

Establishment units

Physical locations of this company

Registered office

Rue du Broux 37

4680 Oupeye

2.215.186.327

Avenue de l'Energie 31 box 20

4432 Ans

Active since 22 October 2012

What is an establishment unit? An establishment unit is a geographically identifiable place where activities of the enterprise are carried out.

Details

Company number

0500.516.337

VAT number

BE 0500.516.337

Registered office

Rue du Broux 37, 4680 Oupeye

Names & denominations

EZI Biolab · EZI Consult

Enterprise type

Rechtspersoon

Legal form

Private limited company

Legal situation

Normale toestand

Start date

2 November 2012

Peppol

Active · Active since 22 Dec 2025

Activities · NACE

Groothandel in parfumerieën en cosmetica

Groothandel in farmaceutische en medische artikelen

Organisatie van congressen en beurzen

Overige vormen van onderwijs

Overige zakelijke dienstverlening, neg

View on CBE Public ↗ Annual accounts (NBB) ↗